Abstract on Provectus Biopharmaceuticals’ PV-10 in Colon Cancer Models Published by Society of Surgical Oncology
June 16 2015 - 6:00AM
Business Wire
Concluded PV-10 “Warrants Further Study as a
Potential Immunotherapeutic Agent”
Published in Abstract Book of SSO’s 68th
Annual Cancer Symposium
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT,
http://www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company (“Provectus” or the “Company”), announced
that the Society of Surgical Oncology (SSO) has published an
abstract describing preliminary research into use of the Company’s
investigational agent, PV-10, in murine models of colon cancer. A
poster based on the published abstract was presented at the SSO’s
68th Annual Cancer Symposium.
Titled, “Intralesional Injection of Rose Bengal Induces an
Anti-tumor Immune Response and Potent Tumor Regressions in a Murine
Model of Colon Cancer,” the abstract detailed research by K.
Pardiwala, G. Qiao, J. Sundararajan, B. Prabhakar, and A.V. Maker
at the University of Illinois at Chicago, Chicago, IL.
Based on their findings, the researchers concluded, “Rose Bengal
induced potent cell death in human and murine colon cancer cells in
vitro. Intralesional injection in established tumors induced an
anti-tumor immune response and significant tumor regressions in
vivo. These studies establish that intralesional PV-10 therapy
warrants further study as a potential immunotherapeutic agent in
colorectal cancer and metastases.”
The SSO has made available all the abstracts from the Symposium
in an electronic supplement to Annals of Surgical Oncology, its
house journal. The abstract on PV-10 can be found on page S86 of
the book, http://expo.jspargo.com/exhibitor/web/SSO15Abstracts.pdf.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company’s other
clinical trials, including its current phase 3 study in melanoma,
can be found at the NIH registry, www.clinicaltrials.gov. For
additional information about Provectus, please visit the Company’s
website at www.pvct.com or contact Porter, LeVay & Rose,
Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2014) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our melanoma drug product candidate, and other solid tumors
such as cancers of the liver, if such licensure is appropriate
considering the timing and structure of such a license, or to
commercialize PV-10 on our own to treat melanoma and other solid
tumors such as cancers of the liver;
- our ability to license our dermatology
drug product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150616005341/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30CFO, COOorPorter, LeVay & Rose, Inc.Marlon
Nurse, 212-564-4700DM, SVP – Investor RelationsorTodd Aydelotte,
646-428-0644Media Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024